Sai Parenterals LimitedPharmaceuticals & HealthcareSAIPARENT
Q1 FY27 concall · earnings callSai Parenterals Limited
The quarter was about improved margins on a seasonally lower revenue base and the strategic reallocation of IPO funds to acquire majority stakes in two operating pharmaceutical assets, accelerating entry into complex injectables and R&D.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Consolidated Total Revenue | ₹182 Cr | — | |
| Gross Profit Margin | 41.8% | 370 bps | |
| EBITDA Margin | 14.9% | 50 bps | |
| Profit After Tax Margin | 4.3% | — | |
| Standalone Revenue Growth (YoY) | 175% | — | |
| Standalone EBITDA Margin | 29% | 890 bps | |
| Gross Debt (as of 30-Jun-2026) | ₹310 Cr | — |
TL;DR
- Q1 revenue of Rs 182 crores was ahead of plan for a Rs 750 crore full-year target.
- Gross margin expanded 370 bps sequentially to 41.8% as price recovery lags began to unwind.
- EBITDA margin improved to 14.9% despite air freight costs to protect Australian supply.
- Board approved reallocation of IPO funds to acquire 60% stakes in Saicriti Pharma (new injectable facility) and Prathyak Labs (established R&D center).
- Australian subsidiary Noumed secured a renewed 7.5-year contract valued at AUD 202 million.
- Management reiterated FY27 guidance of Rs 750 crores revenue and ~17% EBITDA margin.
Said on the call
“FY '27 remains a year of building. FY '28 is when the build should start showing in our performance.”
From the Q&A
| Topic | What management said |
|---|---|
| Large Australian Contract Value | Management clarified that the AUD 202 million contract value is for the existing supply portfolio; new product developments (12 per year) will be incremental to this value. |
| More Order Wins Expected | When asked if more such order wins are expected for Noumed, management answered, 'Yes, there should. That is correct.' |
| Management Bandwidth | Management stated they bet on the potential of the existing teams in acquisitions (like Mark's team at Noumed, the experienced R&D team at Prathyak), rather than Sai doing everything. |
| Rationale for IPO Fund Reallocation | Explained that a new Telangana government policy prohibited upgradations within the outer ring road, forcing a relocation; acquiring the stake in Saicriti saved 6-8 months on land allotment, provided an existing domestic business, and offered a facility with USFDA potential. |
| Downward Trend in Injectable Realizations | Attributed it to the existing facilities not being qualified for EU-GMP, limiting exports to only oral dosages; the new facility is aimed at the ROW and European markets for critical care injectables. |
| Peak Debt and De-leveraging | FY27 is expected to be the peak debt year for the existing business; with the new Saicriti project debt added, the gross debt-to-equity ratio is expected to remain comfortably at ~0.6 times, with de-leveraging from FY28. |
Guidance
- Full-year revenue target of Rs. 750 crores for FY27.
- EBITDA margin of around 17% for FY27.
- Revenue split of 45:55 between the first and second halves of the year.
- Australian facility physical completion targeted for January 2027, with TGA licensing inspection by March 2027 and Phase 1 manufacturing from April 2027.
- New injectable facility (Saicriti) completion extended only about a month to April 2027.
Source
Summary written from the transcript filed by Sai Parenterals Limited for the call held on 12 Aug 2026; published 18 Aug 2026, 21:11 IST.
More Q1 FY27 concalls ·How verification works ·Report an error